GET DAILY SIGNALSMediciNova (MNOV): Monitoring the ALS Catalyst After a Recent -9% Pullback
Key Takeaways
- MediciNova (MNOV) traded near $1.46 in early November 2026, roughly 9% below the closing level recorded about 30 days earlier as an autumn rally unwound.
- The clinical-stage biopharmaceutical remains a data-driven story built around its lead candidate, MN-166 (ibudilast), with topline results from the Phase 2b/3 COMBAT-ALS trial in amyotrophic lateral sclerosis (ALS) expected before the end of 2026.
- A mid-September surge carried the stock to multi-year highs before profit-taking and a mixed Phase 2 readout for MN-001 (tipelukast) pressured the shares.
- MediciNova's cash position of $25.4 million as of June 30, 2026, is expected to fund operations into at least November 2027.
- Sell-side analysts have maintained Buy ratings with published price targets well above current levels, though those targets reflect substantial clinical-execution risk.
- For additional detail on this ticker's Price Targets, Earnings, and Forecast, explore the dedicated pages.
Current Market Snapshot
MediciNova shares have settled into a relatively narrow range after a volatile stretch. Following a sharp run-up in mid-September that carried the stock toward its 52-week high near $3.90, the shares retraced and have largely traded between roughly $1.35 and $1.55 in recent weeks. With a market capitalization of roughly $72 million and thin average daily volume, MNOV behaves like a typical micro-cap clinical-stage biotech, where sentiment can shift quickly on pipeline news rather than quarterly fundamentals. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
MediciNova (MNOV) Business Overview and Competitive Position
MediciNova, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, focused on developing small-molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Its pipeline is built around two compounds with well-characterized safety profiles. MN-166 (ibudilast) is a phosphodiesterase-4 (PDE4) and macrophage migration inhibitory factor (MIF) inhibitor in late-stage development for ALS and degenerative cervical myelopathy (DCM), and Phase 3-ready for progressive multiple sclerosis (MS); it is also being studied in glioblastoma, Long COVID, chemotherapy-induced peripheral neuropathy, and substance use disorder. MN-001 (tipelukast) is an oral anti-inflammatory and anti-fibrotic agent evaluated in Phase 2 trials for non-alcoholic fatty liver disease (NAFLD) and idiopathic pulmonary fibrosis (IPF). The company follows a capital-efficient model, leveraging government grants and academic partnerships to fund investigator-sponsored studies alongside its own programs.
Recent Developments Driving MNOV
The most consequential near-term catalyst is the COMBAT-ALS program. In September 2026, MediciNova announced completion of the last patient, last visit in the double-blind portion of the Phase 2b/3 trial evaluating MN-166 in ALS, which randomized 234 participants across the United States and Canada. The company has guided toward topline results from the double-blind portion before the end of 2026, using the Combined Assessment of Function and Survival (CAFS) as the primary endpoint. Offsetting that optimism, results from a Phase 2 study of MN-001 in patients with NAFLD, type 2 diabetes, and hypertriglyceridemia failed to reach statistical significance on key measures such as triglyceride and liver-fat reduction, contributing to the stock's pullback. Regulatory filings also showed that large shareholder 3D Investment Partners trimmed its position by approximately 640,000 shares, a reduction of more than 11% of its stake. Meanwhile, the company's Q3 2026 earnings report is expected in mid-November, with a consensus loss estimate of $0.06 per share.
2026 Outlook and What Investors Should Watch
The defining event for MediciNova remains the year-end 2026 topline readout from COMBAT-ALS, which will largely determine whether the lead asset advances toward a registrational path in ALS. Additional data points expected through late 2026 and into 2027 include topline results from the Phase 2 OXTOX trial in chemotherapy-induced peripheral neuropathy, topline results from the Phase 2 MN-001-NATG-202 metabolic study, and final patient follow-ups in the NIH-funded SEANOBI-ALS expanded-access program in early 2027. Investors should also monitor the company's cash runway and any future financing activity, as clinical-stage companies typically rely on capital raises to fund development. As with all binary clinical readouts, outcomes carry meaningful risk in both directions, and micro-cap liquidity can amplify price moves. From what I see, this is important because the binary nature of the readout could drive significant volatility.
Exploring Tickeron AI Tools for Biotech Analysis
In my view, Tickeron’s Trending AI Robots page offers a practical way to review automated strategies across many tickers, including those in the biotech space. The curated selection highlights top-performing bots with details on win rates, returns, and risk parameters, allowing investors to match approaches to their own objectives without needing to build systems from scratch. I have found this resource useful when evaluating systematic options alongside manual research on names like MNOV.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MNOV in -4.23% downward trend, sliding for three consecutive days on October 20, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where MNOV declined for three days, in 228 of 290 cases, the price declined further within the following month. The odds of a continued downward trend are 79%.
Technical Analysis (Indicators)
Bearish Trend Analysis
MNOV moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MNOV crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
The Aroon Indicator for MNOV entered a downward trend on October 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MNOV's RSI Indicator exited the oversold zone, 26 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 72 cases where MNOV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on MNOV as a result. In 73 of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for MNOV just turned positive on October 28, 2026. Looking at past instances where MNOV's MACD turned positive, the stock continued to rise in 42 of 53 cases over the following month. The odds of a continued upward trend are 79%.
Following a +5.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where MNOV advanced for three days, in 129 of 193 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.928) is normal, around the industry mean (3.498). P/E Ratio (-6.952) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (135.135) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. MNOV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MNOV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company, which develops small molecule therapeutics
Industry Biotechnology
Advertisement